Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma

Cancer

Volumn 80, Issue 9, 1997, Pages 1760-1767

  Yoshida, Ken Ichiro ^a   Sumi, Shuhei ^a   Arai, Kyoko ^a   Koga, Fumitaka ^a   Umeda, Hiroshi ^a   Hosoya, Yoshikatsu ^a   Honda, Mikihiko ^a   Yano, Masataka ^a   Moriguchi, Hideo ^a   Kitahara, Satoshi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Carboxyterminal propeptide of Type I procollagen (PICP); Carboxyterminal pyridinoline cross linked telopeptide of Type I collagen (ICTP); Prostate carcinoma; Prostate specific antigen (PSA)

Indexed keywords

ANTIANDROGEN; COLLAGEN DERIVATIVE; COLLAGEN TYPE 1; GONADORELIN DERIVATIVE; PROCOLLAGEN TYPE 1 CARBOXYPROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; COLLAGEN METABOLISM; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RADIOIMMUNOASSAY;

AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030722274     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1760::AID-CNCR10>3.0.CO;2-3     Document Type: Article

References (24)

1. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993; 71:1297-302.
2. Pollen JJ, Gerberk K, Ashburn WL, Schmidt JD. Nuclear bone imaging in metastatic cancer of the prostate. Cancer 1981;47:25W, Hosking DJ. Calcium excretion (Ca E) in metastatic breast cancer. Br J Surg 1983;70:202-4.
3. Pollen JJ, Gerberk K, Ashburn WL, Schmidt JD. Nuclear bone imaging in metastatic cancer of the prostate. Cancer 1981;47:25W, Hosking DJ. Calcium excretion (Ca E) in metastatic breast cancer. Br J Surg 1983;70:202-4.
4. Campbell PC, Blamey RW, Woolfson AM, Elston CW, Hosking DJ. Calcium excretion (CaE) in metastatic breast cancer. Br J Surg 1983;70:202.
5. Blomqvist C, Elomaa L, Virkkunen P, Porkka L, Karonen LSL, Risteli J. The response evaluation of bone metastases in mammary carcinoma. The evaluation of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer 1987;60:2907-12.
6. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 1994;151:909-13.
7. Stepan JJ, Mikulecky M, Bek V, Broulik P, Pacovsky V. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastasis and patients with primary hyperparathyroidism. Neoplasma 1989;36:495-501.
8. Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I, Rubens RD. Biochemical prediction of response of bone metastases to treatment. Br J Cancer 1988;58:205-10.
9. Takeuchi S-i, Yoshida K-i. Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastasis. Jpn J Urol 1994;85:1521-7.
10. Mekko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxy-terminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-32.
11. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1996;39:635-40.
12. Soloway MS, Hardeman SW, Hickey D, Raymond JT, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
13. Corrie D, Timmons JH, Bauman JM, Thompson IM. Efficacy of followup bone scans in carcinoma of the prostate. Cancer 1988;61:2453-4.
14. Smith PH, Bono A, Calais Da Silva F, Debruyne F, Dennis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. a subanalysis of EORTC trial 30853. Cancer 1990;66(Suppl 5):1009-21.
15. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites, a controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993;29A: 821-5.
16. Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol 1994;46:173-8.
17. Blomqvist C, Risteli I, Risteli J, Virkkunen P, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996;73:1074-9.
18. Takeuchi S-i, Arai K, Saitoh H, Yoshida K-i, Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 1996;156:1691-5.
19. Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K-i. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastasis in patients with prostate carcinoma. Eur Urol 1997;31:220-3.
20. Akimoto S, Akakura K, Shimazaki J. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Jpn J Clin Oncol 1996;26:157-63.
21. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21:337-44.
22. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-9.
23. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-52.
24. Kylmala T, Tammela TLJ, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995;71: 1061-4.